ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

チクロチアジド

Cyclothiazide

HCID 2910
ノート反応
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
2259-96-3
標準SMILES
NS(=O)(=O)c1cc2c(cc1Cl)NC(C1CC3C=CC1C3)NS2(=O)=O
InChIKey
BOCUKUHCLICSIY-UHFFFAOYSA-N
分子式
C14H16ClN3O4S2
平均分子量
389.9 g/mol
単同位体質量
389.027076

概要

Cyclothiazide is 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted at positions 3, 5 and 6 by a 2-norbornen-5-yl group, chlorine, and a sulfonamide group, respectively. A thiazide diuretic, it has been used in the management of hypertension and oedema. It has a role as a diuretic and an antihypertensive agent.

名称と識別子

優先名称
Cyclothiazide
IUPAC
3-(2-bicyclo[2.2.1]hept-5-enyl)-6-chloro-1,1-dioxo-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide
現地名
チクロチアジド
英語名
Cyclothiazide
分子式
C14H16ClN3O4S2
分子量
389.88

名称と別名

cyclothiazide2259-96-3AnhydronAquirelFluidilRenazideValmiranDoburilCiclotiazidaCiclotiazideCyclothiazidumMDi 193
名称をさらに表示
レナジドアキレルバルミランアクアドールアンヒドロムシクロチアジドリリー35483ドブリル2-(3,6-メタノシクロヘキセン-4-イル)-6-スルファモイル-7-クロロ-1,2-ジヒドロ-3H-4-チアキナゾリン4,4-ジオキシド6-クロロ-3,4-ジヒドロ-3-(ノルボルナ-5-エン-2-イル)-2H-1,2,4-ベンゾチアジアジン-7-スルホンアミド1,1-ジオキシド3-[ビシクロ[2.2.1]ヘプタン-2-エン-6-イル]-6-クロロ-3,4-ジヒドロ-2H-1,2,4-ベンゾチアジアジン-7-スルホンアミド1,1-ジオキシド3,4-ジヒドロ-6-クロロ-3-(ノルボルナ-5-エン-2-イル)-7-スルファモイル-2H-1,2,4-ベンゾチアジアジン1,1-ジオキシドフルイジルアクイレル6-クロロ-3,4-ジヒドロ-3-[ビシクロ[2.2.1]ヘプタ-5-エン-2-イル]-2H-1,2,4-ベンゾチアジアジン-7-スルホンアミド1,1-ジオキシドシクロチアジド (異性体混合物)6-クロロ-3,4-ジヒドロ-3-(2-ノルボルネン-5-イル)-2H-1,2-4-ベンゾチアジアジン-7-スルホンアミド1,1-ジオキシド (異性体混合物)シクロチアジド (AS)チクロチアジド

物性

構造計算による物性

XLogP
2
極性表面積
135 Ų
水素結合供与体数
3
水素結合受容体数
7
回転可能結合数
2
重原子数
24
形式電荷
0
複雑度
758

実験および物理化学的性質

LogP · 3 件

log Kow = 1.95

1.6

1.8

OdorPRACTICALLY ODORLESS
Color/Form · 2 件

CRYSTALS FROM DILUTE ALCOHOL

WHITE TO NEARLY WHITE POWDER

Solubility · 2 件

FREELY SOL IN ACETONE, ETHYL ACETATE, METHANOL; SPARINGLY SOL IN ALC; PRACTICALLY INSOL IN WATER; PRACTICALLY INSOL IN CHLOROFORM, ETHER

2.79e-01 g/L

Human Drugs · 3 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

Melting Point · 3 件

229-230

234 °C

227 - 228 °C

Physical DescriptionSolid
Stability/Shelf LifeTABLETS, EXPIRATION DATE OF 5 YR
Dissociation ConstantsPKA: 10.7 IN WATER
Collision Cross Section195.12 Ų [M+K]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 41 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesSkin Irrit. 2 (100%)

安全と保護具

Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

毒性情報

Interactions · 5 件

...DIURETICS MAY INCR CONCN OF CLOTTING FACTORS BY LOSS OF PLASMA VOL & INCR CLOTTING FACTOR SYNTH BY REDUCING HEPATIC CONGESTION, THEREBY ANTAGONIZING EFFECT OF ORAL ANTICOAGULANTS. /DIURETICS, THIAZIDE/

CONCURRENT ADMIN OF THIAZIDE DIURETICS & MONOAMINE OXIDASE INHIBITORS MAY INCR HYPOTENSION. /THIAZIDE DIURETICS/

化学と産業

薬理情報

ATC Code · 2 件

C - Cardiovascular system

QC - Cardiovascular system

Pharmacodynamics · 1 件

Like other thiazides, cyclothiazide promotes water loss from the body (diuretics). It inhibits Na<sup>+</sup>/Cl<sup>-</sup> reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Cyclothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Cyclothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate.

Mechanism of Action · 6 件

Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.

関連反応

0 件
反応記録を作成

現在のフィルター条件では反応記録がありません。

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
チクロチアジド (JAN)
Lil
35483
mdi193
Aquador
Lilly 35,483DTXSID30228716-Chloro-3,4-dihydro-3-(5-norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxideNSC-758431P71U09G5BW6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide6-Chloro-3,4-dihydro-3-(2-norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide6-Chloro-3-(2-norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide

データベース識別子

CAS
2259-96-3
PubChem CID
2910
DTXSID
DTXSID3022871
ChEMBL
CHEMBL61593
ChEBI
CHEBI:31448
UNII
P71U09G5BW
EC Number
218-859-7

物理化学的性質

融点
234 ° · 234°
比重(密度)
1.3781 · 1.3781 (rough estimate)
屈折率
1.61 · 1.6100 (estimate)
貯蔵温度
2 · 2-8°C
溶解性
DMSO (最大 35mg/ml) またはエタノール (最大 9mg/ml) に可溶。
酸解離定数(Pka)
9.1 · pKa 9.1(30% EtOH) (Uncertain)
外見
白からオフホワイトの固体。
色
オフホワイト
Merck
14 · 14,2754
安定性
-20 °Cで最大3か月保存できます。 · DMSO溶液またはエタノール溶液で-20°Cで最大3か月保存できます。
InChI
1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
InChIKey
BOCUKUHCLICSIY-UHFFFAOYSA-N
EPAの化学物質情報
2 H-1,2,4-Benzothiadiazine-7-sulfonamide, · 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-, 1,1-dioxide (2259-96-3)

...HYPOKALEMIA MAY INTENSIFY ACTION OF NEUROMUSCULAR BLOCKING AGENTS. ... POTASSIUM-DEPLETING DIURETICS ARE KNOWN TO CAUSE HYPOKALEMIA & MAY ENHANCE THIS EFFECT. /DIURETICS/

THIAZIDES ENHANCE ANTIHYPERTENSIVE ACTION OF GUANETHIDINE, ALLOWING DOSE OF GUANETHIDINE TO BE REDUCED & DECR INCIDENCE OF ADVERSE REACTIONS... /THIAZIDES/

For more Interactions (Complete) data for CYCLOTHIAZIDE (23 total), please visit the HSDB record page.

Human Toxicity Excerpts · 2 件

CLINICAL TOXICITY...USUALLY RESULTS FROM UNEXPECTED HYPERSENSITIVITY. CASES HAVE BEEN REPORTED WITH PURPURA, DERMATITIS WITH PHOTOSENSITIVITY, DEPRESSION OF FORMED ELEMENTS OF BLOOD, & NECROTIZING VASCULITIS... /BENZOTHIADIAZIDES/

May suppress lactation, but compatible /SRP: with breast feeding/. /From table/

Drug Induced Liver Injury · 4 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Cyclothiazide

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Non-Human Toxicity ExcerptsPOTASSIUM DEPLETION CAN OCCUR.
Antidote and Emergency TreatmentThiazide diuretic overdose should be treated by immediate evacuation of the stomach followed by supportive symptomatic treatment and monitoring of serum electrolyte concentrations and renal function. /Thiazide diuretic/

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

wgk
2
rtecs
DK9610000
毒性
LD50 oral in rat: > 5gm/kg
hs_code
2935904000
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36
ストレージクラス
11 - Combustible Solids
有毒物質データの
2259-96-3(Hazardous Substances Data)

...BENZOTHIADIAZIDES HAVE DIRECT EFFECT ON RENAL TUBULAR TRANSPORT OF SODIUM & CHLORIDE THAT IS INDEPENDENT OF ANY EFFECT ON CARBONIC ANHYDRASE. ... /THEY/... HAVE PARALLEL DOSE-RESPONSE CURVES & COMPARABLE MAX CHLORURETIC EFFECTS. /BENZOTHIADIAZIDES/

RENAL ACTIONS OF THIAZIDE DIURETICS DECR EXTRACELLULAR FLUID & PLASMA VOL, CARDIAC OUTPUT, & TOTAL EXCHANGEABLE SODIUM IN INDIVIDUALS WITHOUT ANY EVIDENCE OF CARDIAC FAILURE. ...SODIUM & WATER DEPLETION...BASIS FOR ANTIHYPERTENSIVE EFFECT. ...DIURETIC THIAZIDES RELAX PERIPHERAL ARTERIOLAR SMOOTH MUSCLE. /BENZOTHIADIAZIDES/

...AS ANTIHYPERTENSIVE AGENTS...EFFECTS APPEAR TO RESULT FROM ALTERED SODIUM BALANCE. ...DRUG-INDUCED SODIUM EXCRETION AS DETERMINANT OF REDUCTION OF BLOOD PRESSURE IS SUGGESTED...PERIPHERAL VASCULAR RESISTANCE IS DECR...DIRECT ACTION...ON ARTERIOLAR SMOOTH MUSCLE HAS BEEN SUGGESTED. /BENZOTHIADIAZIDES/

Thiazide diuretics increase urinary excretion of sodium and water by inhibiting sodium reabsorption in the early distal tubules. They increase the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and increase in aldosterone levels promote sodium reabsorption at the distal tubules, thus increasing the loss of potassium and hydrogen ions. /Thiazide diuretics/

For more Mechanism of Action (Complete) data for CYCLOTHIAZIDE (7 total), please visit the HSDB record page.

MeSH Pharmacological Classification · 2 件

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Agents that promote the excretion of urine through their effects on kidney function.

Absorption, Distribution and Excretion · 2 件

THIAZIDES ARE RAPIDLY ABSORBED FROM GI TRACT...MOST...SHOW DEMONSTRABLE DIURETIC EFFECT WITHIN HR AFTER ORAL ADMIN. ...THIAZIDES WITH RELATIVELY LONG DURATIONS...SHOW...BOTH BINDING TO PLASMA PROTEINS & REABSORPTION BY RENAL TUBULES. /THIAZIDES/

...THIAZIDES PROBABLY UNDERGO ACTIVE SECRETION IN PROXIMAL TUBULE. RENAL CLEARANCES OF DRUGS ARE HIGH & MAY BE EITHER ABOVE OR BELOW RATE OF FILTRATION. MOST COMPD ARE RAPIDLY EXCRETED WITHIN 3 TO 6 HR. /THIAZIDES/

Cellular LocationsCytoplasm
Metabolite PathwaysCyclothiazide Action Pathway

用途と製造

UsesTHERAP CAT: Diuretic; antihypertensive. THERAP CAT (VET): Diuretic.
Methods of Manufacturing · 2 件

Prepn: C.W. Whitehead et al., J Org Chem 26, 2814 (1961); E. Muller, K. Hasspacher, U.S. pat 3,275,625 (1966 to Boehringer, Ong).

3-CHLOROANILINE IS ACYLATED WITH CHLOROSULFONIC ACID TO PRODUCE 4,6-DISULFONYL CHLORIDE WHICH IS THEN AMIDATED WITH AMMONIA TO GIVE 4,6-DISULFONAMIDE. HEATING LATTER WITH 5-NORBORNENE-2-CARBOXALDEHYDE RESULTS IN CYCLIZATION THROUGH DOUBLE CONDENSATION. PATENT 3,275,625.

Use ClassificationPharmaceuticals

応用分野

使用Cyclothiazide has been used as a α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) desensitization blocker to study the effects of γ2 on receptor desensitization.

一般的な説明Cyclothiazide is a benzothiadiazine, which has a similar structure to diazoxide.

上流・下流製品情報

上流原料

4-アミノ-6-クロロ-1,3-ベンゼンジスルホンアミド

サプライヤー64 社

国药集团化学试剂有限公司86-21-63210123 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
成都超九八生物科技有限公司13348960310 13348960310 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]
上海麦克林生化科技股份有限公司021-50706066 15221275939 · [email protected]
上海优宁维生物科技股份有限公司15921930842 15921930842 · [email protected]
上海毕得医药科技股份有限公司400-1647117 13681763483 · [email protected]
上海仲因实业有限公司2537653158 16621191650 · [email protected]
Syntechem Co.,Ltd[email protected]
北京索莱宝科技有限公司010-50973130 17801761073 · [email protected]
武汉易泰科技有限公司上海分公司18930552037 · [email protected]
安耐吉化学&3A(安徽泽升科技有限公司)021-58432009 400-005-6266 · [email protected]
梯希爱(上海)化工贸易有限公司021-61109150 · [email protected]
InvivoChem中国13549236410 · [email protected]
MedBio脉铂医药021-69568360 18916172912 · [email protected]
怀化市冰峰化工有限公司0745-2866851 17711757908 · [email protected]
銳迪國際科技有限公司18024082417 · [email protected]
Ascent Scientific4401179829988 · [email protected]
凯试(上海)科技有限公司021-50135380 · [email protected]
医恩医疗系统研发(上海)有限公司021-58958002 18930822973 · [email protected]
湖北扬信医药科技有限公司0714-3999001 19171453112 · [email protected]
AdooQ BioScience, LLC+1 (866) 930-6790 · [email protected]
TCI AMERICA800-4238616 · [email protected]
TOKYO CHEMICAL INDUSTRY CO., LTD.03-36680489 · [email protected]
TCI Europe320-37350700 · [email protected]
南京生利德生物科技有限公司025-57798810 18652991625 · [email protected]
上海毕得医药科技股份有限公司400-164-7117 18317119277 · [email protected]
杭州宇昊化工科技有限公司0571-82693216 · [email protected]
南京百鑫德诺生物科技有限公司025-58849295 · [email protected]
Chongqing jooe co., ltd+86-15223382610 · [email protected]
青岛海智微元生物科技有限公司18317699790 18317699790 · [email protected]
Sigma-Aldrich西格玛奥德里奇(上海)贸易有限公司021-61415566 800-8193336 · [email protected]
上海陶术生物科技股份有限公司+1-781-999-5354; +1-00000000000 · [email protected]
BOC Sciences16314854226; +8616314854226 · [email protected]
艾吉析科技(上海)有限公司17717235263 17717235263 · [email protected]
风咏生物(AbMole)021-10000000 13000000000 · [email protected]
上海珞珐生化科技有限公司021-51111890 15317326293 · [email protected]
上海一飞生物科技有限公司021-65675885 18964387627 · [email protected]
上海源叶生物科技有限公司18916372613 · [email protected]
成都华纯科技有限公司400-1166-196 15982826727 · [email protected]
BOC Sciences[email protected]
上海林栎生物科技有限公司13761635123 · [email protected]
Shaanxi Didu New Materials Co. Ltd+86-86-17392712779 +86-13289823923 · [email protected]
江苏艾康生物医药研发有限公司025-58859352 19370895928 · [email protected]
career henan chemical co+86-0371-86658258 · [email protected]
上海瀚香生物科技有限公司17754423994 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386, 800-988-0390 · [email protected]
TCI Chemicals (India) Pvt. Ltd.[email protected]
Aladdin Scientific[email protected]
陕西缔都医药化工有限公司029-029-029-81148696 18161915376 · [email protected]
補足説明 · 1 件

定義ChEBI: 3,4-Dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted at positions 3, 5 and 6 by a 2-norbornen-5-yl group, chlorine, and a sulfonamide group, respectively. A thiazide diuretic, it has been used in the management of hypertension a d oedema.